Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (417)	10/1/1998 5:21:00 PM
From: RealMuLan	Read Replies (3) \| Respond to of 857

CBOE to List Options on HEMISPHERIx BIOPHARMA, Inc. on Thursday, Oct. 8 Thursday October 1, 3:04 pm Eastern Time Company Press Release SOURCE: Chicago Board Options Exchange CHICAGO, Oct. 1 /PRNewswire/ -- The Chicago Board Options Exchange (CBOE) today announced it will begin trading options on HEMISPHERIx BIOPHARMA, Inc. (Amex: HEB; CBOE) on Thursday, Oct. 8. HEMISPHERIx BIOPHARMA, Inc., located in Philadelphia, Pa., is a biopharmaceutical company that uses nucleic acid technologies to develop therapeutic products for the treatment of viral diseases and disorders of the immune systems. HEB options will trade on the February expiration cycle with introductory expirations in October, November, February and May. Initial strike prices have been set at 5, 7 1/2 and 10. Susquehanna Investment Group has been named the Designated Primary Market Maker (DPM) in the options. CBOE, regulated by the Securities and Exchange Commission (SEC), is the pioneer of listed options and the world's largest options marketplace. For additional information about the CBOE and its products, access the CBOE site on the World Wide Web at cboe.com. SOURCE: Chicago Board Options Exchange

To: RealMuLan who wrote (417)	10/3/1998 1:09:00 AM
From: Cavalry	Respond to of 857

business week oh business week what is your deal, playing botrh sides of the fence to sell mags????? Business Week: March 17, 1997 Inside Wall Street PEPPED UP OVER CHRONIC FATIGUE We aren't biotech investors, ''but we've bought into Hemispherx BioPharma--the only biotech in our portfolio,'' says Richard Sinise of Kennedy Capital Management in St. Louis, which manages some $1.5 billion. Sinise isn't the only believer. Investors Larry Tisch and Gerry Tsai also are stakeholders in the young company. What's so hot about Hemispherx (HEMX)? The stock sure hasn't been on a roll: Now at 21/2, it has traded between 2 and 4 since July. The company has a portfolio of 200 patents for technologies that use ribonucleic-acid molecules in products to treat viral diseases, certain cancers, and immune-system dysfunction. One of its major products is Ampligen, now in its third clinical tests for treatment of chronic fatigue syndrome (CFS), hepatitis B, and HIV. The trials, approved by the Food & Drug Administration, are under way in 30 sites. An Ampligen diagnostic-test kit has received patent approval in 10 European countries. It checks blood cells for immune deficits believed to be characteristic of CFS. The Centers for Disease Control & Prevention has included CFS as a ''priority one disease'' on its list of ''new, reemerging, and drug-resistant infectious diseases,'' says Dr. William Carter, chairman and CEO of Hemispherx. There isn't any approved therapy for CFS, he says, adding that a protocol using Ampligen for treatment of CFS patients has been submitted to the FDA for approval. Ampligen, he claims, relieves all the symptoms of CFS, including pain. Carter says Hemispherx has signed a manufacturing pact with Pharmacia-Upjohn, which has taken a 2% stake in Hemispherx. Analyst David Watumull of First Honolulu Securities, says Hemispherx--''at just $140 million in market cap--represents a compelling investment value.'' BY GENE G. MARCIAL Copyright 1997 The McGraw Hill Companies, Inc. All rights reserved. Any use is subject to (1) terms and conditions of this service and (2) rules stated under ''Read This First'' in the ''About Business Week'' area. Transmitted: 3/6/97 6:23 PM (B3518115)

To: RealMuLan who wrote (417)	10/3/1998 1:14:00 AM
From: Cavalry	Read Replies (1) \| Respond to of 857

did doc carter compare heb to ge here, he has a point re patents=$$$ New Drug Compounds Have Potential to Become the First Broad Spectrum Treatment for CFS, HIV and Hep B Infections PHILADELPHIA, May 21 /PRNewswire/ -- HEMISPHERx Biopharma, Inc. (Nasdaq: HEMX) announced today the receipt of the 300th patent to which HEMX has exclusive rights in the area of treating devastating chronic viral diseases including chronic fatigue syndrome (CFS), hepatitis B (hep B) and HIV infections. Termed Oragen(TM) drugs, the compounds are low molecular weight RNA designer drugs which the Company believes have the potential to become the first oral, broad-spectrum treatment for various major viral diseases such as CFS, HIV and hep B infections. In some parts of the world, more than 20% of the populations are infected with these diseases. Results from in vitro studies conducted in collaboration with the National Institute of Allergy and Infectious Diseases, as well as the National Cancer Institute, indicate that the Oragen product may have broad-spectrum activities. Oragen drugs can potentially be engineered to trigger specific responses in immune cells based on in vitro tests. The patent recently issued to Temple University from the United States patent office entitled "Dual action oligoadenylate antiviral derivatives" is part of the HEMX licensing alliance with Temple University. The Company focus is on both novel antiviral strategies as well as developing therapeutics to rearm the body's immune system, often defective in chronic viral diseases such as hep B, HIV and CFS. In commenting on the patented technology, HEMX's CEO, Dr. William Carter, stated: "This exceptionally innovative drug discovery program produced new drug products which carries multiple payloads needed to address the chronic infection -- namely, an antiviral warhead and an immune enhancement device." HEMX now holds one of the very largest patent portfolios in the entire biopharmaceutical sector. In commenting on the Company's expanding patent portfolio breadth and depth, Dr. Carter said: "Perhaps few of us remember that the most highly valued company in the world, G.E., with a market capitalization of $180 billion, had its inception and growth because of the vast patent estate developed by one man, Dr. Thomas Edison. During his lifetime, he set the U.S. record of 1,250 patents. I feel his unique career is a powerful model for how to build a multinational company in the competitive global marketplace we now face in pharmaceutical development for untreatable chronic epidemic diseases. These diseases can destroy not only human health but potentially ruin entire national economies. " HEMISPHERx is a biopharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral disease and disorders of the immune system. HEMX is working with regulatory agencies, physicians and its customers to help ensure that epidemic diseases are prevented, managed and cured with maximum benefit and minimum costs to patients and society. HEMISPHERx corporate web site is www.hemispherx.com SOURCE HEMISPHERx Biopharma Inc.